Polypharmacy and Environmental Chemical Sensitivity Amplification (CYP450 Interactions) — household safety profile
Moderate risk40% of adults over 65 take 5+ medications (polypharmacy).
What is this product?
40% of adults over 65 take 5+ medications (polypharmacy). Many common medications inhibit CYP450 enzymes that also metabolize environmental chemicals — creating competitive inhibition that slows chemical detoxification. CYP3A4 (metabolizes 50% of drugs): inhibited by ketoconazole, erythromycin, grapefruit juice, diltiazem — also metabolizes many pesticides and VOCs. CYP2D6 (metabolizes 25% of drugs): inhibited by fluoxetine, paroxetine, bupropion — poor metabolizer phenotype in 7-10% of Caucasians. CYP1A2: inhibited by fluvoxamine, ciprofloxacin — metabolizes PAHs and aromatic amines. Result: elderly on multiple medications clear environmental chemicals more slowly, increasing effective dose from the same exposure level.
What's in it
Click any compound name for its full safety profile, regulatory consensus, and exposure data.
No compound composition on file for this product.
Frequently asked questions
No FAQs generated.
Look up Polypharmacy and Environmental Chemical Sensitivity Amplification (CYP450 Interactions) in the home app
Search by ingredient, browse by category, or compare to alternatives in the live app.
Open in home View raw API dataReference data, not professional advice. Aggregates publicly available regulatory and scientific information. Why we built ALETHEIA →